Successful treatment of refractory focal eosinophilic myositis with extra-ocular muscle involvement using tocilizumab: a case report - Top-Institutions - MDSpire

Successful treatment of refractory focal eosinophilic myositis with extra-ocular muscle involvement using tocilizumab: a case report

  • By

  • Haijun Liu

  • Qianhua Li

  • Xia Ouyang

  • Shuyu Chen

  • Henglun Liang

  • Yufeng Ye

  • Huiyuan Cao

  • Yong Xue

  • Lie Dai

  • May 25, 2026

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Department of Rheumatology and Immunology
    Department of Rheumatology and Immunology

    Unknown, Unknown

    Key Differentiators

    • Rheumatology

  • #2

    Thoracic Surgery Unit
    Thoracic Surgery Unit

    Unknown, Unknown

    Key Differentiators

    • Surgery

  • #3

    University Hospital of Cologne
    University Hospital of Cologne

    Cologne, North Rhine-Westphalia

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Tyson Eye
    Tyson Eye

    Unknown, Unknown

    Key Differentiators

    • Ophthalmology

  • #5

    Juntendo University Urayasu Hospital
    Juntendo University Urayasu Hospital

    Urayasu, Chiba

    Key Differentiators

    • Rheumatology

Original Source(s)

Successful treatment of refractory focal eosinophilic myositis with extra-ocular muscle involvement using tocilizumab: a case report

  • by Haijun Liu, Qianhua Li, Xia Ouyang, Shuyu Chen, Henglun Liang, Yufeng Ye, Huiyuan Cao, Yong Xue, Lie Dai

  • May 25, 2026

Related Content

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.